IDiyas

For the Inventor, By the Inventor

Suzhou, China

Yifan Zhai

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal17 out of 30 
 
Ascentage Pharma (suzhou) Co., Ltd.
 patents
silverMedal8 out of 20 
 
Ascentage Pharma Group Corp Limited
 patents
where one patent can have more than one assignee

Years Active: 2022-2025

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 12370197 - Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2025-07-29),
2. 12343352 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors (2025-07-01),
3. 12287338 - Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway (2025-04-29),
4. 12268665 - Combination of immunotherapies with MDM2 inhibitors (2025-04-08),
5. 12233047 - Pharmaceutical combination and use thereof (2025-02-25),
6. 12194024 - Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease (2025-01-14),
7. 12186304 - Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule (2025-01-07),
8. 12083136 - Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof (2024-09-10),
9. 11850239 - MDM2 inhibitor and a platinum compound for cancer treatment (2023-12-26),
10. 11554127 - Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP (2023-01-17),
11. 11491168 - Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof (2022-11-08),
12. 11491167 - Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2022-11-08),
13. 11478477 - Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor (2022-10-25),
14. 11478470 - Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases (2022-10-25),
15. 11478469 - Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases (2022-10-25),

Title: Yifan Zhai: Innovator in Cancer Treatment

Introduction

Yifan Zhai is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of cancer treatment. With a total of 17 patents to his name, Zhai has focused on developing innovative therapies that target hematological malignancies.

Latest Patents

Among his latest patents is a combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent. This invention provides a method for the prevention and treatment of diseases, particularly cancer. The combination product includes a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof. This combination is designed for the preparation of a medicament aimed at treating hematological malignancies. Another notable patent involves N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors, which outlines methods for treating hematologic malignancies through a step-wise dosing regimen.

Career Highlights

Yifan Zhai has worked with Ascentage Pharma, a leading company in the biopharmaceutical sector. His role at Ascentage Pharma (Suzhou) Co., Ltd. and Ascentage Pharma Group Corp Limited has allowed him to contribute to groundbreaking research and development in cancer therapies.

Collaborations

Zhai has collaborated with notable professionals in his field, including Dajun Yang and Douglas Dong Fang. These partnerships have further enhanced his research and innovation efforts.

Conclusion

Yifan Zhai's work in developing innovative cancer treatments showcases his dedication to improving patient outcomes. His patents reflect a commitment to advancing medical science and providing new hope for those affected by hematological malignancies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…